Daniel J. Drucker

Daniel J. Drucker's AcademicInfluence.com Rankings

Daniel J. Drucker

Philosophy

#2375

World Rank

#4082

Historical Rank

Logic

#576

World Rank

#1039

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Daniel J. Drucker Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Daniel Joshua Drucker is a Canadian endocrinologist. A Fellow of the Royal Society, he is a professor of medicine at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto. He is known for his research into intestinal hormones and their use in the treatment of diabetes and other metabolic diseases.

(See a Problem?)

Daniel J. Drucker's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (2006) (3465)
Biology of incretins: GLP-1 and GIP. (2007) (3087)
The biology of incretin hormones. (2006) (1983)
Pharmacology, physiology, and mechanisms of incretin hormone action. (2013) (1052)
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. (2015) (1017)
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways (2008) (964)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (2008) (944)
Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. (1987) (811)
Induction of intestinal epithelial proliferation by glucagon-like peptide 2. (1996) (807)
Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene (1996) (801)
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection (2003) (720)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells (2011) (716)
Normalization of Obesity-Associated Insulin Resistance through Immunotherapy: CD4+ T Cells Control Glucose Homeostasis (2009) (623)
The role of gut hormones in glucose homeostasis. (2007) (617)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. (2018) (612)
Enhancing incretin action for the treatment of type 2 diabetes. (2003) (602)
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. (2000) (594)
Incretin-based therapies for type 2 diabetes mellitus (2009) (594)
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* (2003) (549)
Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. (2004) (548)
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. (2000) (537)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice (2009) (515)
Cardiovascular biology of the incretin system. (2012) (500)
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. (2002) (499)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. (2009) (489)
Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. (2003) (485)
Biological actions and therapeutic potential of the glucagon-like peptides. (2002) (481)
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. (2010) (475)
International Union of Pharmacology. XXXV. The Glucagon Receptor Family (2003) (457)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans (2013) (450)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents (2014) (439)
Glucagon-like peptide 1 (GLP-1) (2019) (438)
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors (2014) (414)
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure (2013) (409)
Improvement of Glucose Tolerance and Hepatic Insulin Sensitivity by Oligofructose Requires a Functional Glucagon-Like Peptide 1 Receptor (2006) (399)
The Cardiovascular Biology of Glucagon-like Peptide-1. (2016) (399)
Minireview: the glucagon-like peptides. (2001) (399)
Chemical characterization of leptin‐activated neurons in the rat brain (2000) (369)
GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress (2006) (360)
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. (2004) (356)
Predicting cardiac complications in patients undergoing non-cardiac surgery (1986) (355)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors (2017) (350)
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. (2004) (344)
Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. (1994) (329)
Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. (1999) (326)
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. (2003) (325)
Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. (2000) (322)
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. (2004) (321)
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks (2010) (318)
Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. (1997) (314)
Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications (2020) (312)
Microbial modulation of energy availability in the colon regulates intestinal transit. (2013) (310)
Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. (2005) (305)
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. (2005) (302)
Glucagon-Like Peptides (1998) (301)
Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. (2007) (298)
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits (2010) (297)
Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes (2007) (290)
Cardiovascular actions of incretin-based therapies. (2014) (289)
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. (2013) (283)
Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. (2003) (279)
Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. (1994) (277)
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice (2011) (274)
Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites (2003) (273)
Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice (2010) (270)
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. (2007) (268)
Vertical Sleeve Gastrectomy Is Effective in Two Genetic Mouse Models of Glucagon-Like Peptide 1 Receptor Deficiency (2013) (262)
Modulation of taste sensitivity by GLP‐1 signaling (2008) (262)
Glucagon gene expression in vertebrate brain. (1988) (259)
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. (2008) (258)
Advances in oral peptide therapeutics (2019) (257)
Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. (2001) (256)
Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV (1997) (255)
Inactivation of the winged helix transcription factor HNF3alpha affects glucose homeostasis and islet glucagon gene expression in vivo. (1999) (252)
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls (2013) (250)
Tissue-Specific Role of Glycogen Synthase Kinase 3β in Glucose Homeostasis and Insulin Action (2008) (249)
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. (2004) (249)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice (2010) (245)
Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. (1997) (245)
The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. (2014) (240)
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes (2003) (237)
Biologic actions and therapeutic potential of the proglucagon-derived peptides (2005) (220)
Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. (2014) (220)
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. (2003) (219)
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. (2010) (209)
Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. (1999) (208)
The glucagon receptor is required for the adaptive metabolic response to fasting. (2008) (208)
GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. (2006) (208)
Cardiac function in mice lacking the glucagon-like peptide-1 receptor. (2003) (206)
β-Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1 (2005) (206)
A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity (2013) (205)
Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling (2012) (202)
Islet α cells and glucagon—critical regulators of energy homeostasis (2015) (199)
Discovery, characterization, and clinical development of the glucagon-like peptides. (2017) (198)
Glucagon-like Peptide 2 (1999) (195)
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice (2005) (188)
Insulin Secretion Depends on Intra-islet Glucagon Signaling. (2018) (183)
Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. (2003) (182)
Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. (2002) (173)
Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard* (1997) (171)
Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. (2009) (169)
Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. (1998) (168)
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. (2014) (164)
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM (2013) (162)
Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids (2019) (161)
The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice. (2017) (160)
Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. (2014) (154)
Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues. (1990) (153)
Therapeutic approaches to preserve islet mass in type 2 diabetes. (2006) (153)
Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice (2007) (152)
The safety of incretin-based therapies--review of the scientific evidence. (2011) (151)
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. (2012) (149)
Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice (2009) (149)
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning (2021) (148)
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. (2001) (147)
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. (2011) (144)
Glucagon gene 5'-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. (1992) (143)
Liver-Specific Disruption of the Murine Glucagon Receptor Produces α-Cell Hyperplasia (2013) (140)
GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R (2015) (140)
Activation of proglucagon gene transcription through a novel promoter element by the caudal-related homeodomain protein cdx-2/3 (1996) (137)
Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. (1999) (137)
Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. (1989) (136)
GLP-1 Receptor Expression Within the Human Heart (2018) (135)
Alpha-cell-specific expression of the glucagon gene is conferred to the glucagon promoter element by the interactions of DNA-binding proteins (1988) (135)
Resveratrol Increases Glucose Induced GLP-1 Secretion in Mice: A Mechanism which Contributes to the Glycemic Control (2011) (134)
Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. (1997) (134)
Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. (2005) (133)
Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes (2014) (131)
Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. (1999) (129)
An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. (2008) (129)
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. (2012) (129)
Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. (1997) (128)
The Glucagon Receptor Family (2000) (127)
iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy. (2016) (126)
Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing (2008) (126)
Biological determinants of intestinotrophic properties of GLP-2 in vivo. (1997) (125)
Variable adrenocortical function in acute medical illness (1985) (123)
Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity (2008) (121)
Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription. (1999) (119)
Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice (2008) (118)
Gut adaptation and the glucagon-like peptides (2002) (117)
Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. (1998) (116)
Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling* (2001) (115)
Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. (1998) (114)
Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. (2000) (114)
Identification of Glucagon-like Peptide-2 (GLP-2)-activated Signaling Pathways in Baby Hamster Kidney Fibroblasts Expressing the Rat GLP-2 Receptor* (1999) (113)
The parathyroid hormone-like peptide gene is expressed in the normal and neoplastic human endocrine pancreas. (1989) (113)
Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion. (2017) (113)
Exendin-4 modulates diabetes onset in nonobese diabetic mice. (2008) (113)
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. (2009) (113)
Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. (2006) (112)
Modulation of Taste Sensitivity by GLP‐1 Signaling in Taste Buds (2009) (112)
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. (2009) (110)
Lipopolysaccharides-Mediated Increase in Glucose-Stimulated Insulin Secretion: Involvement of the GLP-1 Pathway (2014) (109)
Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. (2001) (109)
The LIM Domain Homeobox Gene isl-1 Is a Positive Regulator of Islet Cell-specific Proglucagon Gene Transcription(*) (1995) (108)
Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells (2010) (108)
The Glucagon-like Peptide-2 Receptor Mediates Direct Inhibition of Cellular Apoptosis via a cAMP-dependent Protein Kinase-independent Pathway* (2000) (107)
Ciliary neurotrophic factor recruitment of glucagon‐like peptide‐1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons (2009) (106)
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. (2014) (104)
The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. (2008) (101)
Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease (2018) (100)
Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. (2000) (99)
Never Waste a Good Crisis: Confronting Reproducibility in Translational Research. (2016) (98)
GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion (2007) (97)
Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotectionab (2014) (97)
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease (2020) (97)
TCF1 links GIPR signaling to the control of beta cell function and survival (2015) (97)
ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. (2009) (95)
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. (2011) (95)
The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. (2005) (95)
Cytokines Tumor Necrosis Factor-α and Interferon-γ Induce Pancreatic β-Cell Apoptosis through STAT1-mediated Bim Protein Activation* (2011) (94)
Transcriptional regulation of genes encoding insulin, glucagon, and angiotensinogen by sodium butyrate in a rat islet cell line (1987) (94)
Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice (2011) (93)
GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose (2018) (92)
beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. (2005) (92)
Precision medicine in the management of type 2 diabetes. (2018) (92)
Glucagon-like Peptide-2 Receptor Activation Engages Bad and Glycogen Synthase Kinase-3 in a Protein Kinase A-dependent Manner and Prevents Apoptosis following Inhibition of Phosphatidylinositol 3-Kinase* (2002) (92)
Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension (2019) (91)
Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence. (1998) (90)
Glucagon and glucagon-like peptide receptors as drug targets. (2006) (90)
Immunocytochemical localization of parathyroid hormone-like peptide in the rat fetus. (1991) (89)
Proglucagon-derived peptides: mechanisms of action and therapeutic potential. (2005) (88)
Ghrelin Is a Novel Regulator of GLP-1 Secretion (2014) (88)
Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition. (2019) (88)
Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. (1986) (85)
Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity (2012) (85)
Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. (2000) (85)
Glucagon-like Peptide-2. (2006) (84)
GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. (2015) (84)
Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. (2004) (83)
Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. (2009) (82)
Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes (2017) (81)
Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine. (2019) (81)
Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. (2004) (81)
Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. (2000) (79)
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. (2009) (79)
Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. (1999) (79)
UVB radiation induces p21Cip1/WAF1 and mediates G1 and S phase checkpoints. (1996) (79)
Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. (2011) (78)
Oxyntomodulin regulates resetting of the liver circadian clock by food (2015) (78)
Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat–Fed Diabetic Mice (2015) (77)
Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. (2016) (77)
Liver-Speci ﬁ c Disruption of the Murine Glucagon Receptor Produces a -Cell Hyperplasia: Evidence for a Circulating a -Cell Growth Factor (2012) (74)
Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. (1998) (74)
The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice (2016) (73)
Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. (2000) (73)
Islet cell and extrapancreatic expression of the LIM domain homeobox gene isl-1. (1991) (73)
Parathyroid hormone-like peptide shares features with members of the early response gene family: rapid induction by serum, growth factors, and cycloheximide. (1992) (72)
Regulation of Glucagon-Like Peptide-1 Synthesis and Secretion in the GLUTag Enteroendocrine Cell Line* * This work was supported by grants from the Canadian Diabetes Association (Margaret A. Mollet grant, to P.L.B.) and Eli Lilly. (1998) (72)
Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor-/- Mice. (1998) (71)
Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. (2001) (71)
Phenotypic Characterization of MIP-CreERT1Lphi Mice With Transgene-Driven Islet Expression of Human Growth Hormone (2015) (71)
Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis. (2017) (71)
Glucagon gene 5'-flanking sequences promote islet cell-specific gene transcription. (1987) (71)
Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. (2003) (71)
Glucagon‐like peptide‐1 is specifically involved in sweet taste transmission (2015) (71)
Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. (1997) (70)
Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling1. (2000) (70)
Adrenocortical dysfunction in acute medical illness (1986) (69)
Revisiting the complexity of GLP-1 action-from sites of synthesis to receptor activation. (2020) (69)
Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats (2009) (68)
New frontiers in the biology of GLP-2 (2000) (68)
Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. (2011) (68)
Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis. (2012) (68)
Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. (2004) (67)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling (2020) (67)
Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. (2010) (66)
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. (1999) (66)
A Switch From Prohormone Convertase (PC)-2 to PC1/3 Expression in Transplanted α-Cells Is Accompanied by Differential Processing of Proglucagon and Improved Glucose Homeostasis in Mice (2007) (65)
ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. (2010) (64)
GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. (2011) (63)
Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. (2000) (63)
Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture (2015) (62)
Enhancing the action of incretin hormones: a new whey forward? (2006) (62)
Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior (2015) (62)
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications (2018) (62)
Body weight homeostat that regulates fat mass independently of leptin in rats and mice (2017) (61)
Parathyroid hormone-related peptide is a downstream target for ras and src activation. (1994) (61)
Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy (2014) (60)
Fibroblast activation protein (FAP) as a novel metabolic target (2016) (59)
Activation of Glucagon-Like Peptide-1 Receptor Signaling Does Not Modify the Growth or Apoptosis of Human Pancreatic Cancer Cells (2006) (59)
Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. (1999) (59)
Developmental and tissue-specific regulation of proglucagon gene expression. (1990) (58)
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice. (2019) (58)
Glucagon gene transcription in an islet cell line is regulated via a protein kinase C-activated pathway. (1987) (58)
Structural determinants for activity of glucagon-like peptide-2. (2000) (57)
The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. (2005) (57)
The rat glucagon gene is regulated by a protein kinase A-dependent pathway in pancreatic islet cells. (1991) (57)
Reactive human bile ductules express parathyroid hormone‐related peptide (1993) (55)
The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription. (1995) (54)
Pax-6 activates endogenous proglucagon gene expression in the rodent gastrointestinal epithelium. (2003) (54)
Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction (2014) (54)
Glucagon receptor signaling is essential for control of murine hepatocyte survival. (2008) (53)
Intensive insulin therapy in newly diagnosed type 2 diabetes (2008) (53)
Parathyroid hormone‐related peptide expression in primary and metastatic liver tumours (1993) (53)
The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice (2017) (53)
Characterization and functional role of voltage gated cation conductances in the glucagon‐like peptide‐1 secreting GLUTag cell line (2005) (53)
Cardiovascular Surgery in the Hypothyroid Patient (1985) (52)
Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse. (2009) (52)
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. (2008) (52)
Hyperthyroxinemia in patients with acute psychiatric disorders. (1983) (50)
Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. (2007) (50)
Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose. (2013) (50)
Proglucagon gene expression and posttranslational processing in a hamster islet cell line. (1988) (50)
Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats. (1996) (50)
Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action. (2019) (50)
Energy Homeostasis and Gastrointestinal Endocrine Differentiation Do Not Require the Anorectic Hormone Peptide YY (2005) (50)
Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. (1997) (49)
Glucagon and the Glucagon‐like Peptides (1990) (49)
Glucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis (2014) (49)
Glucagon and related peptides in fetal rat hypothalamus in vivo and in vitro. (1990) (48)
Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. (2017) (48)
Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21 (2018) (46)
Evolving Concepts and Translational Relevance of Enteroendocrine Cell Biology. (2016) (46)
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance. (2016) (45)
Epithelial cell growth and differentiation. I. Intestinal growth factors. (1997) (45)
Lipid raft-dependent glucagon-like peptide-2 receptor trafficking occurs independently of agonist-induced desensitization. (2004) (45)
GLP-1 physiology informs the pharmacotherapy of obesity (2021) (45)
Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. (2010) (44)
Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology (2011) (44)
Alterations in proglucagon processing and inhibition of proglucagon gene expression in transgenic mice which contain a chimeric proglucagon-SV40 T antigen gene. (1992) (44)
Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice* (2000) (44)
Ultraviolet radiation induction of ornithine decarboxylase in rat keratinocytes. (1990) (43)
The caudal homeobox protein cdx-2/3 activates endogenous proglucagon gene expression in InR1-G9 islet cells. (1997) (43)
Rapid induction of parathyroid hormone-like peptide gene expression by sodium butyrate in a rat islet cell line. (1991) (43)
The Glucagon-like Peptide-2 Receptor C Terminus Modulates β-Arrestin-2 Association but Is Dispensable for Ligand-induced Desensitization, Endocytosis, and G-protein-dependent Effector Activation* (2005) (42)
The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice (2019) (42)
Treatment of type 2 diabetes with the designer cytokine IC7Fc (2019) (42)
Aberrant regulation of human intestinal proglucagon gene expression in the NCI-H716 cell line. (2003) (42)
L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling (2020) (41)
Activation of amylin gene transcription by LIM domain homeobox gene isl-1. (1996) (41)
Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes. (1989) (40)
Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor. (2002) (40)
Insulin Action in the Double Incretin Receptor Knockout Mouse (2008) (40)
Multiple cis-acting domains mediate basal and adenosine 3',5'-monophosphate-dependent glucagon gene transcription in a mouse neuroendocrine cell line. (1993) (40)
The Cushing syndrome induced by medroxyprogesterone acetate. (1989) (40)
Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression. (2002) (39)
Inhibition of pancreatic glucagon gene expression in mice bearing a subcutaneous glucagon-producing GLUTag transplantable tumor. (1992) (39)
Activation of Enteroendocrine Membrane Progesterone Receptors Promotes Incretin Secretion and Improves Glucose Tolerance in Mice (2012) (39)
Glucagon-like peptide 2. (1997) (38)
UVB radiation-activated genes induced by transcriptional and posttranscriptional mechanisms in rat keratinocytes. (1995) (37)
Brain GLP-1 Signaling Regulates Femoral Artery Blood Flow and Insulin Sensitivity Through Hypothalamic PKC-δ (2011) (37)
Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents (2018) (37)
Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice. (2012) (36)
Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes (2005) (36)
Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1 (2002) (36)
Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas. (1986) (36)
Regulation of parathyroid hormone-related peptide (PTHrP) gene transcription: cell- and tissue-specific promoter utilization mediated by multiple positive and negative cis-acting DNA elements. (1992) (35)
N-Glycan Remodeling on Glucagon Receptor Is an Effector of Nutrient Sensing by the Hexosamine Biosynthesis Pathway* (2014) (35)
Proglucagon gene expression is induced by gastrin-releasing peptide in a mouse enteroendocrine cell line. (1996) (35)
Exceptional Lie Algebras and the Structure of Hermitian Symmetric Spaces (1978) (33)
Regulation of peptide-YY synthesis and secretion in fetal rat intestinal cultures. (1991) (33)
Divergent regulation of human and rat proglucagon gene promoters in vivo. (1999) (33)
Cardiovascular safety and diabetes drug development (2011) (33)
Ethionamide-induced goitrous hypothyroidism. (1984) (32)
Gipr Is Essential for Adrenocortical Steroidogenesis; However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr−/− Mice (2011) (32)
Identification of Domains Mediating Transcriptional Activation and Cytoplasmic Export in the Caudal Homeobox Protein Cdx-3* (1999) (32)
Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis (2008) (31)
Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. (2003) (30)
The endogenous preproglucagon system is not essential for gut growth homeostasis in mice (2017) (30)
Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. (1994) (29)
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans (2020) (29)
Clinical decisions. Management of type 2 diabetes. (2008) (29)
New Developments in the Biology of the Glucagon‐Like Peptides GLP‐1 and GLP‐2 (2000) (29)
Thyroiditis as the presenting manifestation of disseminated extrapulmonary Pneumocystis carinii infection. (1990) (28)
Ectopic Expression of GIP in Pancreatic β-Cells Maintains Enhanced Insulin Secretion in Mice With Complete Absence of Proglucagon-Derived Peptides (2013) (28)
Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway (2017) (28)
Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling. (2003) (27)
Leptin Sensitivity in Nonobese Glucagon-Like Peptide I Receptor −/− Mice (1997) (27)
Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice. (1998) (27)
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. (2009) (27)
Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion (2020) (26)
Integrating global proteomic and genomic expression profiles generated from islet alpha cells: opportunities and challenges to deriving reliable biological inferences. (2005) (26)
GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9 (2018) (26)
The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanism. (2021) (26)
Incretin-Based Therapy and the Quest for Sustained Improvements in β-Cell Health (2011) (25)
Pax-2 activates the proglucagon gene promoter but is not essential for proglucagon gene expression or development of proglucagon-producing cell lineages in the murine pancreas or intestine. (2002) (24)
Foxa3 (HNF-3gamma) binds to and activates the rat proglucagon gene promoter but is not essential for proglucagon gene expression. (2002) (24)
Localization of Glucagon-like Peptide-2 Receptor Expression in the Mouse. (2019) (24)
Glucagon Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T Cell Proliferation. (2019) (24)
Expression of Peptide Hormone Genes in Human Islet Cell Tumors (1988) (23)
Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice (2001) (23)
Biologic properties and therapeutic potential of glucagon-like peptide-2. (1999) (23)
Exendin-(9-39) Is an Inverse Agonist of the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3',5'-Monophosphate Levels and β-Cell Glucose Competence* *This work was supported by Grant 31-46958.96 from the Swiss National Science Foundation (to B.T.). (1998) (23)
Tales beyond the crypt: glucagon-like peptide-2 and cytoprotection in the intestinal mucosa. (2005) (22)
Experimental and clinical pharmacology (2008) (22)
Growth factor-like properties of parathyroid hormone-related peptide in transfected rodent cell line. (1993) (22)
Physiological roles of the GIP receptor in murine brown adipose tissue (2019) (22)
The LIM domain homeobox gene isl-1: conservation of human, hamster, and rat complementary deoxyribonucleic acid sequences and expression in cell types of nonneuroendocrine lineage. (1994) (22)
Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter–Exendin-4 (MT-Exendin) Transgenic Mice (2006) (22)
Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport (2017) (22)
Oxyntomodulin increases intrinsic heart rate through the glucagon receptor (2013) (21)
lucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and hylomicron Production via CD 36 (21)
Synthesis and secretion of somatostatin-28 and -14 by fetal rat intestinal cells in culture. (1990) (20)
Differential expression of RNA transcripts encoding unique carboxy-terminal sequences of human parathyroid hormone-related peptide. (1994) (20)
Parathyroid hormone‐like peptide in normal and neoplastic mesothelial cells (1990) (19)
The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome. (2019) (19)
GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr−/− mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy (2018) (18)
β-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation (2017) (18)
Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice (2016) (18)
Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice (2009) (18)
Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide (2021) (18)
Genetic variation in Glp1r expression influences the rate of gastric emptying in mice. (2008) (17)
- Cell Pdx 1 Expression Is Essential for the Glucoregulatory , Proliferative , and Cytoprotective Actions of Glucagon-Like Peptide-1 (2005) (17)
GPR 119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms (2010) (15)
Pdx-1 is not sufficient for repression of proglucagon gene transcription in islet or enteroendocrine cells. (2005) (15)
Development of colonic and pancreatic endocrine tumours in mice expressing a glucagon-SV40 T antigen transgene (1996) (15)
Divergent regulation of human and rat proglucagon gene promoters in vivo. (1999) (15)
Glucagon-Like Peptide-1 Receptor Activation Inhibits Growth and Augments Apoptosis in Murine CT 26 Colon Cancer Cells (2011) (14)
Mouse Pancreatic-Cells Exhibit Preserved Glucose Competence After Disruption of the Glucagon-Like Peptide-1 Receptor G e n e (1998) (14)
Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. (2022) (13)
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. (2021) (13)
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice (2010) (13)
Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice (2018) (13)
Conference coverage: Selected presentations from the 20th Annual Practical Approaches to the Treatment of Obesity; June 22-24, 2006 (2006) (12)
Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency. (2011) (12)
The past 10 years—new hormones, new functions, new endocrine organs (2015) (12)
Pathophysiology of Beta Cell Failure After Prolonged Remission of Insulin-dependent Diabetes Mellitus (IDDM) (1984) (12)
RATIONAL MAPPINGS OF DEL PEZZO SURFACES, AND SINGULAR COMPACTIFICATIONS OF TWO-DIMENSIONAL AFFINE VARIETIES (1984) (12)
Region- and age-specific differences in proglucagon gene expression in the central nervous system of wild-type and glucagon-simian virus-40 T-antigen transgenic mice. (1993) (12)
Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes (2021) (11)
Glucagon-like Peptide-1 Receptor Signaling Modulates (2002) (11)
Ultraviolet B radiation induction of ornithine decarboxylase gene expression in mouse epidermis. (1990) (11)
Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling (2018) (11)
GLP-1 receptor (GLP-1R) agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte (IEL) GLP-1R (2015) (11)
Graphical evaluation of sparse determinants (1979) (11)
Incretin-Based Therapies (2006) (11)
Glucagon Gene Expression (2003) (11)
β-Cell Replication by Loosening the Brakes of Glucagon-Like Peptide-1 Receptor Signaling (2008) (11)
Parathyroid hormone—like peptide (1991) (10)
Perfect graphs and complex surface singularities with perfect local fundamental group (1989) (10)
Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice. (2020) (10)
A Natural Classification of Curves and Surfaces With Reflection Properties (1996) (10)
Molecular pathophysiology of glucagon-SV40 T antigen transgenic mice. (1994) (10)
The gut hormone receptor GIPR links energy availability to the control of hematopoiesis (2020) (10)
A Second Look at Descartes' Rule of Signs (1979) (10)
GRAPH THEORETIC TECHNIQUES IN ALGEBRAIC GEOMETRY I: THE EXTENDED DYNKIN DIAGRAM Ē8 AND MINIMAL SINGULAR COMPACTIFICATIONS OF C2 (1981) (9)
GLP-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice (2009) (9)
TCF 1 links GIPR signaling to the control of beta cell function and survival (2015) (9)
GLP-1 receptor signaling differentially modifies the outcomes of sterile vs. viral pulmonary inflammation in male mice. (2020) (9)
Glucagon-Like Peptide-2 Stimulates S-Phase Entry of Intestinal Lgr5+ Stem Cells (2022) (8)
The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue. (2022) (8)
Posttranslational modification of prothyroid hormone. (1983) (8)
Glucagon-like peptide-I and glucagon-like peptide-2 (2004) (8)
Transforming type 1 diabetes: the next wave of innovation (2021) (8)
Interaction of TPA and ultraviolet B radiation in regulation of ODC gene expression in rat keratinocytes. (1992) (8)
On the Number of Solutions of ∑sj = 1(1/xj) + 1/(x1 · · · xs) = 1 (1993) (7)
Glucagon-like peptide 1 and type 1 diabetes: NOD ready for prime time? (2007) (7)
On the discriminant of a trinomial (1984) (7)
Atrial fibrillation after administration of calcium and pentagastrin. (1981) (7)
Differential glucocorticoid regulation of glucagon gene expression in cell lines derived from rat and hamster islet cell tumors. (1991) (6)
Bladder pheochromocytoma in pregnancy without hypertension. A case report. (1995) (6)
Glucagon gene 3'-flanking sequences direct formation of proglucagon messenger RNA 3'-ends in islet and nonislet cells lines. (1990) (6)
Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation. (2022) (6)
Hematopoietic cell– versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice (2020) (6)
Regulation of glucose kinetics during exercise by the glucagon‐like peptide‐1 receptor (2012) (6)
cis-acting DNA sequence controls glucagon gene expression in pancreatic islet cells. (1987) (6)
CHAPTER 39 – Gastrointestinal Hormones and Gut Endocrine Tumors (2011) (6)
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy (2022) (6)
Euclidean hypersurfaces with reflection properties (1990) (6)
Glucagon-like peptide 2: an update (2005) (6)
A Comprehensive Pythagorean Theorem for All Dimensions (2015) (5)
Reflection Properties of Curves and Surfaces (1992) (5)
Survival in Cells Expressing a Transfected GLP-2 Receptor Chemotherapy-associated Mortality and Enhances Cell Glucagon-like Peptide ( GLP )-2 Reduces Updated (2001) (5)
Simplified descriptions of the exceptional bounded symmetric domains (1981) (5)
TUMOR NECROSIS FACTOR- α AND INTERFERON- γ INDUCE PANCREATIC β -CELL APOPTOSIS THROUGH STAT1-MEDIATED BIM ACTIVATION (2011) (5)
Molecular and cellular analysis of a neoplastic pancreatic a cell tumor (1990) (5)
Irreducible Root Systems and Finite Linear Groups of Degree Two (1982) (4)
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis (2022) (4)
GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice (2022) (4)
Unraveling the complexities of gut endocrinology (2007) (4)
Intestinal Proglucagon-Derived Peptides (1999) (4)
Pseudotumour cerebri in association with polyarthritis, urticaria and cryoglobulinemia. (1985) (4)
Graph theoretic techniques in algebraic geometry II: construction of singular complex surfaces of the rational cohomology type of CP2 (1981) (4)
A Comparison of Mode-Acceleration and Ritz Vector Reduced Basis Procedures in Transient Analysis (1988) (4)
Three Matrix Factorizations from the Steps of Elimination (2022) (4)
Proglucagon-Derived Peptides, GIP and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue. (2019) (4)
Differences in the central anorectic effects of GLP-1 and exendin-4 in rats Running title : Central GLP-1 and exendin-4 (2009) (4)
Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction (2022) (3)
GIPR Signaling in Immune Cells Maintains Metabolically Beneficial Type 2 Immune Responses in the White Fat From Obese Mice (2021) (3)
Predicting relapse in acute bronchial asthma. (1982) (3)
iology of Incretins : GLP-1 and GIP (3)
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1 (2022) (3)
Understanding Incretin Hormone Action and the Treatment of Diabetes (2012) (3)
The Evidence for Achieving Glycemic Control With Incretin Mimetics (2006) (3)
Inappropriate TSH secretion with abnormal thyrotroph sensitivity to dopamine. (1985) (3)
Cellular specificity of proexendin-4 processing in mammalian cells in vitro and in vivo. (2002) (3)
Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: Involvement of the glucagon-like peptide 1 (GLP1) pathway. (2013) (2)
The incretin hormone oxyntomodulin regulates resetting of the liver circadian clock by food (2015) (2)
Molecular pathophysiology of glucagon-SV 40 tag transgenic mice (1993) (2)
Abstract 1004: Administration Of A Glucagon-like Peptide-1 Receptor Agonist Prevents Cardiac Rupture And Increases Survival In Mice Undergoing Myocardial Infarction (2007) (2)
Metabolic Disease Puts Up a Fight: Are diet and exercise helpful for the heart? (2013) (2)
Impact of long chain fatty acids on sweet taste sensitivity in mice. Role of the GPR120/GLP-1 signaling (2011) (1)
Integrating Global Proteomic and Genomic Expression Profiles Generated from Islet α Cells (2005) (1)
TCF7 is not essential for glucose homeostasis in mice (2021) (1)
M1660 The Endogenous Murine GLP-2 Receptor Is Essential for Nutrient Absorption and the Adaptive Mucosal Response to Disorders of Energy Homeostasis (2008) (1)
Reflective Euclidean hypersurfaces (1991) (1)
Essential roles of the gastrin and glucagon genes in the response to experimental murine colitis (2000) (1)
Transgenic mice in the study of endocrine systems (1992) (1)
Proglucagon-derived peptides in the neuroendocrine system. (1991) (1)
CHAPTER 6 – Gastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis (2006) (1)
Abstract 19477: The Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Reduces Inflammation and Improves Cardiac Function in a Mouse Model of Obesity (2010) (1)
When Does Water Find the Shortest Path Downhill? The Geometry of Steepest Descent Curves (2003) (1)
[GLP-2 peptide(glucagon-like peptide-2) controls energetic homeostasis by actions on proliferation and cytoprotection in the gastrointestinal epithelium]. (2004) (1)
Ontogeny of the GLP-2/GLP-2 receptor axis during rat intestinal development (2000) (1)
The incretin receptors for GLP-1 and GIP are essential for the sustained metabolic actions of vildagliptin in mice (2007) (1)
Islet Amyloid Polypeptide/GLP‐1/Exendin (2003) (1)
The neuroprotective efficacy of the DPP-4 inhibitor linagliptin against stroke is not mediated by GLP-1 receptor activation (2015) (1)
Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. (1997) (1)
GI Hormones as Growth Factors (2004) (1)
Single Variable Calculus Early Transcendentals (1995) (0)
THE GLP-2R C-TERMINUS MODULATES β -ARRESTIN-2 ASSOCIATION, BUT IS DISPENSABLE FOR LIGAND-INDUCED DESENSITIZATION, ENDOCYTOSIS, AND G-PROTEIN-DEPENDENT EFFECTOR ACTIVATION (2005) (0)
A 11 Patent Number : 5 , 789 , 379 45 ) Date of Patent : Aug (2017) (0)
362-OR: The Role of Intraislet Glucagon in Pulsatile Insulin Secretion (2022) (0)
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. (2023) (0)
Abstract 1136: Role of Glucagon-Like Peptide-1 in Myocardial Ischemia-Reperfusion Injury (2006) (0)
GLP-2 as an indicator and modulator of acute inflammation improves cardiac function and survival in sepsis (2022) (0)
Peptide-2 glucagon-like. (1997) (0)
independent of the glucagon-like peptide-1 receptor Oxyntomodulin increases intrinsic heart rate in mice (2007) (0)
xyntomodulin and Glucagon-Like Peptide-1 Differentially egulate Murine Food Intake and Energy Expenditure (2004) (0)
ReviewThe biology of incretin hormones (0)
Chapter 34 – Glucagon and the Glucagon-Like Peptides (2016) (0)
255-OR: ADA Presidents’ Select Abstract: Glucagon Receptor Antagonism Stimulates Beta-Cell Proliferation in Mouse and Human Islets (2020) (0)
Glucagon receptor family in GtoPdb v.2021.3 (2021) (0)
IN PRESS lucagon Receptor Signaling Is Essential for Control of Murine epatocyte Survival (0)
Acute DPP-4 Inhibition rapidly Enhances Insulin-mediated Suppression of Endogenous Glucose Production in Mice (2008) (0)
Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders (2012) (0)
GLP1 receptor activation and DPP‐4 inhibition increase GFR and induce natriuresis and diuresis in mice (2011) (0)
Péptido-2 de tipo glucagón y su uso terapéutico (1996) (0)
balance in mice Exercise training changes autonomic cardiovascular (2015) (0)
Alterations of cytoplasmic Ca2+ regulation in mouse islets unresponsive to GLP-1 (1998) (0)
n Albumin-Exendin-4 Conjugate Engages Central and Peripheral ircuits Regulating Murine Energy and Glucose Homeostasis (0)
Running title: LPS enhances Glucagonlike peptide 1 (2013) (0)
GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose (2018) (0)
Erratum. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073–1081 (2017) (0)
The Role of Pancreatic Pre proglucagon in Glucose Homeostasis in Mice Graphical Abstract Highlights (2017) (0)
Bernard Zinman: A Canadian Clinician Scientist Changing the Management of Diabetes (2022) (0)
Glucagon‐like peptide‐1 receptor is a regulator of glucose clearance in oxidative tissues independent of insulin (2008) (0)
Glucagon-like peptide 1 (GLP-1). (2019) (0)
GLP-1-mediated delivery of the PPAR𝛼/𝛾 dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice (2021) (0)
Endocrine targets related to COVID19 infection (2020) (0)
Peptide-2 analogue au glucanon (1997) (0)
Peptide in Transfected Rodent Cell Lines Growth Factor-like Properties of Parathyroid Hormone-related Updated (2006) (0)
Glucagon-like Peptide ( GLP )-2 Reduces Chemotherapy-associated Mortality and Enhances Cell Survival in Cells Expressing a Transfected GLP-2 Receptor 1 (2001) (0)
Glucagon-like peptide-1 is involved in the thermic effects of dietary proteins in male rodents. (2023) (0)
Renal effects of glucagon‐like peptide‐1 receptor knockout in Akita‐diabetic mice (2016) (0)
Development and Characterization of Long-Acting Degradation Resistant GLP-1-DAC Compounds for the Treatment of Type 2 Diabetes (2002) (0)
Author response: Oxyntomodulin regulates resetting of the liver circadian clock by food (2015) (0)
S1684 Enhanced or Disrupted GLP-2 Receptor Signaling Fails to Modify Growth or Survival of Murine or Human Intestinal Tumor Cells (2008) (0)
Central GLP-1 receptor signaling directly controls brown adipose tissue thermogenesis (2011) (0)
Glucagon Family of Peptides and their Receptors (2004) (0)
Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets (2023) (0)
Enhancement of intestinal epithelial repair by a human glucagon-like peptide-2 analogue, h[Gly2]-GLP-2, in a murine model of ulcerative colitis (1998) (0)
Glucagon receptor family (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (0)
Beta-endoproteolysis of the cellular prion protein by dipeptidyl peptidase-4 and fibroblast activation protein (2022) (0)
Figure 7 (higher resolution images) (2015) (0)
by Serum , Growth Factors , and Cycloheximide Members of the Early Response Gene Family : Rapid Induction Parathyroid Hormone-like Peptide Shares Features with Updated Version (2006) (0)
Discovery and relevance of the incretin system (2010) (0)
SAT-LB101 Loss of GLP-2R Signaling Activates Hepatic Stellate Cells and Exacerbates Diet-Induced Steatohepatitis in Mice (2020) (0)
Protein Engineering Strategies for Sustained GLP-1R-Dependent Control of Glucose Homeostasis (2008) (0)
Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets (2023) (0)
Glucagon-like Peptide 2 (GLP-2) (2004) (0)
Eight Weeks of Treatment With the Long-Acting Human GLP-1 Analog Taspoglutide ( R 1583 ) Improves Glycemic Control and Lowers Body Weight in Subjects With Type 2 Diabetes Treated With Metformin : A Double-Blind , Placebo-Controlled Phase 2 Study (2008) (0)
Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes? (2005) (0)
Glucagon-like peptide-2 analogues (1997) (0)
Glucagon-like peptide-2 (GLP-2) is a potent mediator of intestinal ApoB48-containing lipoprotein overproduction (2008) (0)
Incretin receptor signalling, [beta]-cell proliferation and survival (2009) (0)
Importance of Glucose-Dependent Insulinotropic Polypeptide vs lucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice (0)
Will Transplantation of an Hepatitis C-Infected Graft Improve the Outcome of Liver Transplantation in HCV Patients? (1999) (0)
Tissue-specific control of glucagon-like peptide-2 receptor expression in mice expressing a GLP-2R-Lacz transgene (2000) (0)
Reduction of DPP-4 Activity on Bone Quality in Mice Differential Effects of PPAR-{ gamma } Activation versus Chemical or Genetic (2011) (0)
iNKT Cells Induce FGF 21 f or Thermogenesis and Are Required for Maximal Weight Loss in GLP 1 Therapy Graphical (2016) (0)
Peptide-2 and glucagon-like therapeutic use. (1996) (0)
Figure 10 (higher resolution) (2015) (0)
696 Genetic Disruption of the Murine Glucagon-Like Peptide 2(GLP-2) Receptor Increases Susceptibility to Indomethacin-Induced Enteritis (2008) (0)
Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease (2019) (0)
Analogs 2-peptidic glucagon. (1997) (0)
Serine/threonine kinase apparentee a ampk, appelee snark (2001) (0)
Abstract 3669: The Glucagon Like Peptide-1 (GLP-1) Metabolite GLP-1(9–36) Protects Cardiomyocytes and Endothelial Cells From Myocardial Ischemia Reperfusion Injury via GLP-1 Receptor-independent Mechanisms (2009) (0)
Abstract 1489: Mechanisms Underlying Cardioprotective Effects Of Glucagon-like Peptide-1 In Ischemia-reperfusion Injury (2007) (0)
Smoking habits in hospital. (1982) (0)
Advances in oral peptide therapeutics (2019) (0)
The expanding incretin universe: from basic biology to clinical translation. (2023) (0)
GLP-1 receptor signaling modulates anorectic GLP-2 action in the murine central nervous system (2001) (0)
Self-inflicted stab wounds to pregnant uterus and fetus at term. (1972) (0)
Young Mothers' Clinic in suburban county hospital. (1973) (0)
A Mathematical Roller Derby. (1992) (0)
A Euclidean interpretation of Dynkin diagrams and its relation to root systems (1987) (0)
Orbit structure of the exceptional Hermitian symmetric spaces. II (1974) (0)
Jacques Salomon Hadamard and the Use of Symbols in Teaching Differential Calculus (2008) (0)
Student solutions manual for Stewart's Single variable calculus, fourth edition (1999) (0)
Student solutions manual for Single variable calculus early transcendentals (2008) (0)
Student solutions manual for Single variable calculus (2008) (0)
GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9 (2018) (0)

This paper list is powered by the following services:

Other Resources About Daniel J. Drucker

en.wikipedia.org

What Schools Are Affiliated With Daniel J. Drucker?

Daniel J. Drucker is affiliated with the following schools:

Daniel J. Drucker's Academic­Influence.com Rankings